A V Balar, D E Castellano, P Grivas, D J Vaughn, T Powles, J Vuky, Y Fradet, J-L Lee, L Fong, N J Vogelzang, M A Climent, A Necchi, D P Petrylak, E R Plimack, J Z Xu, K Imai, B Homet Moreno, J Bellmunt, R de Wit, P H O'Donnell
BACKGROUND: Immune checkpoint inhibitors are a standard therapy in metastatic urothelial carcinoma (UC). Long-term follow-up is necessary to confirm durability of response and identify further safety concerns. PATIENTS AND METHODS: In KEYNOTE-045, patients with metastatic UC that progressed on platinum-containing chemotherapy were randomly assigned 1:1 to receive pembrolizumab or investigator's choice of paclitaxel, docetaxel, or vinflunine. Primary end points were progression-free survival (PFS) per RECIST v1...
December 6, 2022: Annals of Oncology: Official Journal of the European Society for Medical Oncology